However, although TP53 mutations are common in metastatic PCa, it is unclear whether patients with TP53 mutations have a reduced overall survival time compared to patients without TP53 mutations, and it is also unclear whether this effect is dependent on other genetic alterations. This evidence concerns the gene TP53 and posterior cortical atrophy.